Show simple item record

dc.contributor.authorSweetman, D U
dc.contributor.authorMolloy, E J
dc.date.accessioned2013-08-30T10:32:07Z
dc.date.available2013-08-30T10:32:07Z
dc.date.issued2013-03
dc.identifier.citationBiomarkers of acute kidney injury in neonatal encephalopathy. 2013, 172 (3):305-16 Eur. J. Pediatr.en_GB
dc.identifier.issn1432-1076
dc.identifier.pmid23138391
dc.identifier.doi10.1007/s00431-012-1890-6
dc.identifier.urihttp://hdl.handle.net/10147/300394
dc.description.abstractAcute kidney injury (AKI) is a common complication of neonatal encephalopathy (NE). The accurate diagnosis of neonatal AKI, irrespective of the cause, relies on suboptimal methods such as identification of rising serum creatinine, decreased urinary output and glomerular filtration rate. Studies of AKI biomarkers in adults and children have shown that biomarkers can improve the early diagnosis of AKI. Hypoxia-ischaemia is the proposed aetiological basis of AKI in both NE and cardiopulmonary bypass (CPB). However, there is a paucity of studies examining the role of AKI biomarkers specifically in NE. Urinary cystatin C (CysC), neutrophil gelatinase-associated lipocalin (NGAL), interleukin-18, kidney injury molecule-1, liver-type fatty acid-binding protein, serum CysC and serum NGAL all show good ability to predict early AKI in a heterogeneous critically ill neonatal population including infants post-CPB. Moreover, serum and urinary NGAL and urinary CysC are early predictors of AKI secondary to NE. These findings are promising and open up the possibility of biomarkers playing a significant role in the early diagnosis and treatment of NE-related AKI. There is an urgent need to explore the role of AKI biomarkers in infants with NE as establishing the diagnosis of AKI earlier may allow more timely intervention with potential for improving long-term outcome.
dc.language.isoenen
dc.rightsArchived with thanks to European journal of pediatricsen_GB
dc.subjectNEONATE
dc.subject.meshAcute Kidney Injury
dc.subject.meshBiological Markers
dc.subject.meshGestational Age
dc.subject.meshHumans
dc.subject.meshHypoxia-Ischemia, Brain
dc.subject.meshInfant, Newborn
dc.titleBiomarkers of acute kidney injury in neonatal encephalopathy.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Neonatology, National Maternity Hospital, Holles Street, Dublin, Ireland. dee.sweetman@gmail.comen_GB
dc.identifier.journalEuropean journal of pediatricsen_GB
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen
html.description.abstractAcute kidney injury (AKI) is a common complication of neonatal encephalopathy (NE). The accurate diagnosis of neonatal AKI, irrespective of the cause, relies on suboptimal methods such as identification of rising serum creatinine, decreased urinary output and glomerular filtration rate. Studies of AKI biomarkers in adults and children have shown that biomarkers can improve the early diagnosis of AKI. Hypoxia-ischaemia is the proposed aetiological basis of AKI in both NE and cardiopulmonary bypass (CPB). However, there is a paucity of studies examining the role of AKI biomarkers specifically in NE. Urinary cystatin C (CysC), neutrophil gelatinase-associated lipocalin (NGAL), interleukin-18, kidney injury molecule-1, liver-type fatty acid-binding protein, serum CysC and serum NGAL all show good ability to predict early AKI in a heterogeneous critically ill neonatal population including infants post-CPB. Moreover, serum and urinary NGAL and urinary CysC are early predictors of AKI secondary to NE. These findings are promising and open up the possibility of biomarkers playing a significant role in the early diagnosis and treatment of NE-related AKI. There is an urgent need to explore the role of AKI biomarkers in infants with NE as establishing the diagnosis of AKI earlier may allow more timely intervention with potential for improving long-term outcome.


This item appears in the following Collection(s)

Show simple item record